“Newgenco Tang Zhi Shu Capsule” went through all strict formalities of safety evaluation and medical examination (including animal test and human clinical test) according to the standard procedures set out by Chinese regulatory agencies in 2002-2003 and was approved for manufacturing by SFDA of China in 2004. It was extracted from natural buckwheat seeds and contains a new kind of insulin sensitizer—D-chiro-inositol (DCI) & Myo-Inositol (MI) and demonstrated an excellent safety, efficacy profiles and dominant effect on patients with diabetes, hyperlipidemia, hypertension.

“Newgenco Tang Zhi Shu Capsule” was manufactured in a GMP standard by our two patented techniques. We discovered that natural buckwheat (Fagopyrum esculentum Moench, Fagopyrum trtarium Moench) seeds contains large amount of a new important mediator for insulin action in the derivation type.